IO Biotech (IOBT) announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company’s lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Shamsaei joins the company’s executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States. Most recently, she served as Vice President, Head of Commercial at Allogene Therapeutics (ALLO).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOBT:
- IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
- IO Biotech presents data on IO102-IO103 vaccine at AACR 24
- IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
- IO Biotech appoints Faical Miyara as CBO
- IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting